Details of Drug-Drug Interaction
| Drug General Information (ID: DDISF3KT6G) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Pravastatin | Drug Info | Niacin | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Statins/Antihyperlipidemic Agents | Vitamins/Antihyperlipidemic Agents | |||||||
| Structure | |||||||||
| Mechanism of Pravastatin-Niacin Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of other adverse reactions (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Pravastatin | Niacin | |||||||
| Mechanism | Rhabdomyolysis | Rhabdomyolysis | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Adverse reactions | ||||||||
| Factor Description | An adverse reaction is an unexpected negative reaction to a medication or treatment that happens even when it's used correctly. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | The concurrent use of niacin and pravastatin should be avoided unless the benefit outweighs risk. Some authorities suggest that a dose reduction for pravastatin should be considered if concomitant therapy is required. It should also be noted that the risk of adverse effects is increased with niacin doses greater than 1 gram per day. In addition, if patients do receive this combination, they should be instructed to promptly report symptoms of muscular pain, weakness, or tenderness. Creatine kinase should be measured if such symptoms appear. If creatine kinase is elevated or if myopathy is suspected, the drugs should be discontinued. | ||||||||